The medication, doxcycline, has a warning label saying tooth staining may be a side effect of the drug in children under 8.
A study, led by the CDC and Indian Health Service and published in The Journal of Pediatrics, examined medical records for more than 250 children on an Indian Reservation with high rates of RMSF. Dentists looked at the teeth of children who had been treated with doxcycline before turning 8 years old and those who did not. They found no difference in teeth color, staining or enamel.
“Many doctors readily use doxcycline to treat suspected RMSF in adults but won’t use the drug in children because they’re worried about tooth staining and hesitate to prescribe it for only a suspected case,” said Jennifer McQuiston, MD, a CDC epidemiologist. “Our study shows definitively that this shouldn’t be a reason to avoid this life-saving drug. Changing the drug’s label may encourage physicians to use doxcycline earlier to treat suspected RMSF in children, which will help save lives.”
The CDC recommends that physicians start children on doxcycline as soon as they suspect RMSF, because delaying treatment can increase the risk of hospitalization and death.
Doxcycline is also effective in killing bacteria that commonly cause community-acquired pneumonia, according to the CDC.
More articles on antibiotic use:
Homes are hotbeds for transmitting MRSA among inhabitants
McDonald’s to avoid using chickens treated with antibiotics
5 recent stories on antibiotic resistance
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.